Mannose supplementation in PMM2-CDG.

Taday R, Park JH, Grüneberg M, DuChesne I, Reunert J, Marquardt T

Forschungsartikel (Zeitschrift) | Peer reviewed

Zusammenfassung

In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper "Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)" has shown that further investigation of mannose in PMM2-CDG is worthwhile alongside other treatment options and should not be dismissed off-hand without the willingness to prove or disprove it in controlled prospective clinical trials.

Details zur Publikation

FachzeitschriftOrphanet Journal of Rare Diseases
Jahrgang / Bandnr. / Volume16
Ausgabe / Heftnr. / Issue1
Seitenbereich359-359
StatusVeröffentlicht
Veröffentlichungsjahr2021 (11.09.2021)
Sprache, in der die Publikation verfasst istEnglisch
DOI10.1186/s13023-021-01988-x
StichwörterCongenital Disorders of Glycosylation; Dietary Supplements; Humans; Mannose; Phosphotransferases (Phosphomutases); Prospective Studies

Autor*innen der Universität Münster

Park, Julien Heinrich
Klinik für Kinder- und Jugendmedizin - Allgemeine Pädiatrie -